Pfizer says two-third vaccine protection could be reduced by South African variant
According to a lab study, the South African variation of COVID-19 may diminish anti-body protection from Pfizer Inc/BioNTech SE by two-third, and it isn’t clear if the shot will be successful against the mutation, the organizations said on Wednesday.
The researchers found that the vaccine neutralized the virus, but there isn’t any proof yet from preliminaries in individuals that the variation lessens vaccine protection, the organizations said.
In any case, they are making still making investments and conversing with controllers about building up a refreshed adaptation of their mRNA vaccine or a booster shot, if necessary.
Regardless of whether the South Africa variant B.1.351 fundamentally lessens efficacy, the vaccine will still be protective against extreme infection, and death, study co-author Pei-Yong Shi said.